Medical Marijuana During Pregnancy: What the Research Actually Shows

This article is not a recommendation to use medical marijuana during pregnancy. Every major medical organization — the American College of Obstetricians and Gynecologists (ACOG), the American Academy of Pediatrics (AAP), the Society for Maternal-Fetal Medicine, and the CDC — advises against medical marijuana use during pregnancy and breastfeeding.

But a recommendation against use and a clear understanding of the evidence are not the same thing. Pregnant women are already using medical marijuana — an estimated 3-7% of pregnant women in the United States, depending on the survey — and many of them are doing so without accurate information about what the research shows and doesn't show.

This article presents the evidence landscape honestly. Not to encourage use, but because patients deserve to make informed decisions based on data rather than vague warnings or unfounded reassurances.

Why Pregnant Women Use Medical Marijuana

The primary reason pregnant women report using medical marijuana is nausea and vomiting — specifically, hyperemesis gravidarum and severe morning sickness that does not respond adequately to first-line treatments.

A 2019 survey by Young-Wolff et al. in JAMA found that among pregnant women who used medical marijuana:

• 81% reported using it for nausea
• 61% for vomiting
• 52% for stress and anxiety
• 48% for pain
• 39% for improved sleep

A subset of these women had tried standard antiemetics (ondansetron, doxylamine-pyridoxine, metoclopramide) and found them inadequate or intolerable. For women with hyperemesis gravidarum severe enough to require IV fluids and hospitalization, the desperation to find relief is understandable.

The second major driver is mental health: anxiety, depression, and PTSD symptoms that either pre-date or emerge during pregnancy. Some women who were using medical marijuana for these conditions before pregnancy continue use because the alternative — untreated psychiatric symptoms — also carries risks.

The Endocannabinoid System in Pregnancy

The ECS plays a documented role in multiple aspects of pregnancy and fetal development:

• Implantation: Endocannabinoid signaling (particularly anandamide levels in the uterus) regulates embryo implantation. Too much or too little anandamide is associated with implantation failure. A 2005 study by Wang et al. in Journal of Clinical Investigation showed that anandamide levels must be precisely regulated for successful implantation in mice.
• Placental development: CB1 and CB2 receptors are expressed in the placenta. Endocannabinoids participate in trophoblast differentiation and placental vasculature development.
• Fetal brain development: The ECS is one of the earliest neurotransmitter systems to develop in the fetal brain. CB1 receptors appear by gestational week 14 and play roles in neural progenitor cell proliferation, neuronal migration, axon guidance, and synapse formation.
• Fetal stress response: The ECS modulates the fetal hypothalamic-pituitary-adrenal (HPA) axis, which governs the stress response.

The involvement of the ECS in these critical processes is the primary biological rationale for concern: exogenous cannabinoids (THC, CBD) from medical marijuana could theoretically interfere with endocannabinoid signaling during windows of vulnerability in fetal development.

Birth Outcome Evidence

Low Birth Weight

The most consistently reported association is between prenatal medical marijuana exposure and reduced birth weight.

A 2016 meta-analysis by Gunn et al. in BMJ Open pooled data from 24 studies and found:

• Medical marijuana use during pregnancy was associated with a 77% increase in the odds of low birth weight (OR 1.77, 95% CI 1.04-3.01)
• Mean birth weight was approximately 109 grams lower in medical marijuana-exposed infants
• The association was attenuated but persisted after adjusting for tobacco use

A 2020 study by Corsi et al. in JAMA — one of the largest to date, using Ontario health records linking prenatal medical marijuana screening to birth outcomes in over 660,000 pregnancies — found:

• Small-for-gestational-age (SGA) infants: 53% higher odds in medical marijuana users
• Preterm birth: 29% higher odds
• Placental abruption: 72% higher odds
• NICU admission: 40% higher odds

Important caveats:

• The magnitude of the birth weight reduction (~100g) is clinically modest for an individual pregnancy
• Confounding with tobacco use is extremely difficult to eliminate, and many studies have imperfect adjustment for concomitant tobacco exposure
• The Corsi study relied on self-reported medical marijuana use during prenatal screening, and underreporting likely biased the results (the true medical marijuana-using group probably included more heavy users)

Preterm Birth

The preterm birth data is less consistent:

• Some studies (including Corsi) report a modest association
• A 2019 systematic review by Conner et al. in Obstetrics & Gynecology found no significant association between medical marijuana use and preterm birth after controlling for tobacco
• A 2021 retrospective cohort by Luke et al. found an association with preterm birth only among women who used medical marijuana more than once weekly

Stillbirth and Miscarriage

The data on stillbirth and miscarriage is sparse and inconclusive:

• A 2019 study by Chabarria et al. in Obstetrics & Gynecology found an increased risk of stillbirth among medical marijuana users, but the association did not persist after adjustment for tobacco and socioeconomic factors
• No large prospective study has established an independent association between medical marijuana use and miscarriage or stillbirth

Neurodevelopmental Evidence

The longer-term effects on child development are the more concerning — and more uncertain — area of the research.

The Ottawa Prenatal Prospective Study (OPPS)

The OPPS, led by Peter Fried beginning in 1978, followed approximately 200 mother-child pairs from pregnancy through young adulthood. This is the longest-running study of prenatal medical marijuana exposure:

• Infancy: No significant differences in Bayley developmental scores between exposed and unexposed infants
• Ages 3-4: Medical marijuana-exposed children showed deficits in verbal ability and memory on standardized testing
• Ages 5-6: Attention deficits emerged, with exposed children performing worse on sustained attention tasks
• Ages 9-12: Executive function differences became apparent — exposed children had poorer abstract reasoning, visual-spatial planning, and impulse control
• Ages 13-16: Deficits in executive function persisted, and medical marijuana-exposed adolescents were more likely to initiate medical marijuana use themselves
• Young adulthood: Some executive function differences persisted, though the effect sizes were modest

The OPPS has been influential but has significant limitations: small sample size, observational design, no adjustment for some confounders, and a cohort from the 1980s (when medical marijuana potency and usage patterns were different from today).

The Maternal Health Practices and Child Development Study (MHPCD)

The MHPCD, led by Nancy Day and Gale Richardson at the University of Pittsburgh, followed approximately 600 mother-child pairs:

• Ages 3: Medical marijuana-exposed children showed poorer short-term memory and verbal reasoning
• Ages 6: Sleep problems and behavioral issues were more common in the exposed group
• Ages 10: Exposed children showed increased hyperactivity, impulsivity, and inattention — a pattern that mirrors ADHD
• Ages 14: Exposed adolescents showed higher rates of depression, delinquent behavior, and medical marijuana use initiation
• Age 22: Young adults with prenatal exposure showed poorer executive function and abstract reasoning — though many were functioning normally in daily life

The ABCD Study

The Adolescent Brain Cognitive Development (ABCD) study — the largest long-term study of brain development in the United States — has provided neuroimaging data on prenatal medical marijuana exposure. A 2020 analysis by Paul et al. in JAMA Psychiatry found that children aged 9-10 with prenatal medical marijuana exposure showed:

• Greater psychopathology symptoms (anxiety, depression, attention problems)
• Lower cognitive performance on several domains
• Differences in brain structure (reduced cortical thickness in some regions)

However, the effect sizes were small, and the clinical significance of the structural brain differences is unclear.

What the Evidence Doesn't Show

It's important to be specific about what hasn't been established:

• No evidence of major birth defects. Unlike alcohol (which causes fetal alcohol spectrum disorders with recognizable physical features), medical marijuana exposure has not been linked to structural malformations or recognizable dysmorphic syndromes.
• No evidence of intellectual disability. The neurodevelopmental effects, when detected, are subtle — differences in executive function and attention, not global cognitive impairment.
• No clear dose-response relationship. Most studies group all medical marijuana users together. The effects of occasional use versus daily heavy use may be very different, and the existing research cannot reliably distinguish between them.
• No evidence that CBD alone causes fetal harm. The animal and human data primarily involves THC. CBD-specific fetal safety data is essentially nonexistent — which is not the same as saying CBD is safe during pregnancy. The absence of evidence is not evidence of absence.

Why This Research Is So Difficult

The evidence limitations aren't failures of effort — they reflect genuine methodological challenges:

Ethics: You cannot randomize pregnant women to medical marijuana exposure. All human evidence is observational, which means confounding factors are impossible to fully eliminate.

Confounding: Women who use medical marijuana during pregnancy are more likely to also use tobacco, alcohol, and other substances; have lower socioeconomic status; experience more stress; and have less prenatal care. Untangling the effects of medical marijuana from these co-occurring factors is extraordinarily difficult.

Self-report bias: Most studies rely on self-reported medical marijuana use. Underreporting is likely, meaning the "non-exposed" group in many studies probably contains women who actually used medical marijuana — which would bias results toward the null (making medical marijuana look safer than it is).

Potency changes: Medical marijuana today is substantially more potent than what was available during the OPPS (1980s) or even the MHPCD (1990s). Modern products contain 20-30% THC versus 2-4% in earlier decades. Research from earlier eras may underestimate the effects of contemporary medical marijuana use.

Long follow-up required: Neurodevelopmental effects may not manifest until school age or adolescence, requiring expensive and logistically difficult longitudinal studies.

What Medical Organizations Recommend

The consensus across major medical organizations is uniform:

ACOG (2017, reaffirmed 2021): "Women who are pregnant or contemplating pregnancy should be encouraged to discontinue marijuana use. Women reporting marijuana use should be counseled about concerns regarding potential adverse health consequences of continued use during pregnancy."

AAP (2018): "Given the current state of evidence, ACOG and AAP recommend advising all women against using marijuana while pregnant or breastfeeding."

Society for Maternal-Fetal Medicine (2020): Recommends screening for medical marijuana use, advising discontinuation, and connecting patients who cannot stop with behavioral health resources.

These recommendations are based on the precautionary principle: when the evidence suggests possible harm and the long-term consequences involve a developing brain, the conservative approach is to advise against use — even when the evidence is not definitive.

The Breastfeeding Question

THC is transferred into breast milk — this is well-established. A 2018 study by Bertrand et al. in Pediatrics detected THC in 63% of breast milk samples from medical marijuana-using mothers, with THC persisting for up to 6 days after last use.

The clinical significance for the breastfed infant is less clear:

• Infant oral bioavailability of THC from breast milk is unknown
• The amount transferred is small relative to maternal dose
• No studies have directly measured neurodevelopmental outcomes in infants exposed to medical marijuana exclusively through breast milk (as opposed to prenatal exposure)

ACOG and AAP recommend against medical marijuana use during breastfeeding, applying the same precautionary principle as during pregnancy.

The Honest Conversation

If you're pregnant and currently using medical marijuana, or considering it because standard treatments aren't managing your symptoms, here's what a responsible clinician should discuss with you:

1. The evidence suggests possible harm but does not prove definitive harm. The effects, when detected, are subtle and primarily involve executive function and attention — not global cognitive impairment or major birth defects.

1. Stopping use is the safest recommendation based on current evidence. This is the position of every major medical organization, and it's the right default advice.

1. If you cannot stop, reducing use is better than continuing at the same level. Lower frequency and lower THC concentrations are likely (though not proven) to be less risky.

1. Your other risk factors matter. Medical marijuana use in the context of adequate prenatal care, good nutrition, and no tobacco/alcohol use is a different risk profile than medical marijuana use combined with smoking, drinking, and poor prenatal care.

1. The condition you're treating also has consequences. Severe untreated nausea leading to dehydration and malnutrition carries its own risks for fetal development. Severe untreated anxiety and depression during pregnancy are associated with adverse outcomes. The decision framework should include the risks of the untreated condition, not just the risks of the treatment.

The Bottom Line

CORAL does not recommend medical marijuana use during pregnancy. Dr. Kim follows ACOG guidelines and advises pregnant patients to discontinue medical marijuana use.

But we also believe in evidence-based conversations, not fear-based ones. Pregnant patients who are using medical marijuana deserve honest information about what the research shows — and doesn't show — so they can make informed decisions in partnership with their healthcare providers.

If you're not pregnant and want to explore whether medical marijuana might help with a qualifying condition, you can schedule a consultation at [coral.clinic/start](https://coral.clinic/start). Dr. Kim provides the kind of thorough, research-informed evaluation that helps you make the right decision for your situation.

---

This article is for educational purposes only and does not constitute medical advice regarding pregnancy. All decisions about medication use during pregnancy should be made in consultation with your obstetrician or maternal-fetal medicine specialist.